Literature DB >> 26751638

Association of CMV, HBV, or HCV co-infection with vaccine response in adults with well-controlled HIV infection.

S B Troy1,2, A E B Rossheim1, J Siik1, T D Cunningham3, J A Kerry2.   

Abstract

Even after CD4 count recovery on antiretroviral therapy, HIV infection is associated with decreased response to most vaccines compared to the general population. Chronic infections with viruses such as cytomegalovirus (CMV), hepatitis B virus (HBV), and hepatitis C virus (HCV), which are more prevalent in HIV-infected populations, have been linked to immune dysfunction and decreased vaccine response in the general population. However, whether co-infection with these other viruses contributes to the decreased vaccine response seen in adults with well-controlled HIV infection is unknown. We conducted a secondary analysis of data and serum from adults with well-controlled HIV infection from an inactivated polio vaccine trial (224 subjects) and a pneumococcal conjugate vaccine study (128 subjects). We evaluated the association of CMV, HBV, or HCV co-infection with post-vaccination antibody levels using both univariate and multivariate analyses, controlling for factors such as age, race, CD4 count, comorbidities, smoking status, and baseline antibody levels. Ninety-three percent, 7%, and 14% of subjects were co-infected with CMV, HBV, and HCV respectively. On both univariate and multivariate analysis, neither CMV nor HCV co-infection were significantly associated with post-vaccination antibody levels to either vaccine. HBV co-infection was significantly associated with post-vaccination antibody concentrations for pneumococcal serotype 7F on univariate analysis and 6A on multivariate analysis, but the association was with higher antibody concentrations. In conclusion, co-infection with CMV, HBV, or HCV does not appear to contribute to the decreased vaccine response seen in adults with well-controlled HIV infection.

Entities:  

Keywords:  CMV; HBV; HCV; HIV; vaccine response

Mesh:

Substances:

Year:  2016        PMID: 26751638      PMCID: PMC4963073          DOI: 10.1080/21645515.2015.1121336

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  32 in total

1.  Cytomegalovirus infection and responsiveness to influenza vaccination in elderly residents of long-term care facilities.

Authors:  Wendy P J den Elzen; Ann C M T Vossen; Herman J M Cools; Rudi G J Westendorp; Aloys C M Kroes; Jacobijn Gussekloo
Journal:  Vaccine       Date:  2011-04-15       Impact factor: 3.641

2.  The Seroconversion Rate of Hepatitis A Virus Vaccination among Patients with Hepatitis B Virus-Related Chronic Liver Disease in Korea.

Authors:  Hyun Chin Cho; Yu Jin Kim; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Byung Chul Yoo; Seung Woon Paik
Journal:  Gut Liver       Date:  2011-06-23       Impact factor: 4.519

3.  Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination.

Authors:  Evelyna Derhovanessian; Heidi Theeten; Karin Hähnel; Pierre Van Damme; Nathalie Cools; Graham Pawelec
Journal:  Vaccine       Date:  2012-11-26       Impact factor: 3.641

4.  Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease.

Authors:  S D Lee; C Y Chan; M I Yu; Y J Wang; F Y Chang; K J Lo; A Safary
Journal:  J Med Virol       Date:  1997-06       Impact factor: 2.327

5.  Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection.

Authors:  S W Tsang; J J Sung
Journal:  Aliment Pharmacol Ther       Date:  1999-11       Impact factor: 8.171

Review 6.  Residual immune dysregulation syndrome in treated HIV infection.

Authors:  Michael M Lederman; Nicholas T Funderburg; Rafick P Sekaly; Nichole R Klatt; Peter W Hunt
Journal:  Adv Immunol       Date:  2013       Impact factor: 3.543

7.  Influenza-related mortality among adults aged 25-54 years with AIDS in South Africa and the United States of America.

Authors:  Cheryl Cohen; Lone Simonsen; Jeannette Sample; Jong-Won Kang; Mark Miller; Shabir A Madhi; Michael Campsmith; Cecile Viboud
Journal:  Clin Infect Dis       Date:  2012-06-19       Impact factor: 9.079

8.  Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults.

Authors:  Nancy F Crum-Cianflone; Lynn E Eberly; Chris Duplessis; Jason Maguire; Anuradha Ganesan; Dennis Faix; Gabriel Defang; Yun Bai; Erik Iverson; Tahaniyat Lalani; Timothy Whitman; Patrick J Blair; Carolyn Brandt; Grace Macalino; Timothy Burgess
Journal:  Clin Infect Dis       Date:  2010-12-07       Impact factor: 9.079

9.  A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults.

Authors:  Nancy F Crum-Cianflone; Katherine Huppler Hullsiek; Mollie Roediger; Anuradha Ganesan; Sugat Patel; Michael L Landrum; Amy Weintrob; Brian K Agan; Sheila Medina; Jeremy Rahkola; Braden R Hale; Edward N Janoff
Journal:  J Infect Dis       Date:  2010-10-01       Impact factor: 5.226

Review 10.  Functionality of the immune system in patients with chronic hepatitis C: trial by superinfections and vaccinations.

Authors:  Maria G Isaguliants
Journal:  Expert Rev Vaccines       Date:  2007-08       Impact factor: 5.217

View more
  1 in total

Review 1.  CD8+ T Cell Senescence: Lights and Shadows in Viral Infections, Autoimmune Disorders and Cancer.

Authors:  Valentina Tedeschi; Giorgia Paldino; Martina Kunkl; Marino Paroli; Rosa Sorrentino; Loretta Tuosto; Maria Teresa Fiorillo
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.